HOXC9 overexpression is associated with gastric cancer progression and a prognostic marker for poor survival in gastric cancer patients

2020 ◽  
Vol 25 (12) ◽  
pp. 2044-2054
Author(s):  
Xue-Feng Zhao ◽  
Yu-Shen Yang ◽  
Young Kyu Park
2017 ◽  
Vol 213 (8) ◽  
pp. 943-948 ◽  
Author(s):  
Yishui Lian ◽  
Meixiang Sang ◽  
Lina Gu ◽  
Fei Liu ◽  
Danjing Yin ◽  
...  

2019 ◽  
Vol 215 (8) ◽  
pp. 152509 ◽  
Author(s):  
Yan Zhang ◽  
Guo-ming Wen ◽  
Chuan-an Wu ◽  
Zhi-liang Jing ◽  
Da-zhou Li ◽  
...  

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Wang-Yang Pu ◽  
Rong Zhang ◽  
Li Xiao ◽  
Yong-You Wu ◽  
Wei Gong ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Jun Wang ◽  
Zhigang He ◽  
Bo Sun ◽  
Wenhai Huang ◽  
Jianbin Xiang ◽  
...  

Pleckstrin-2 (PLEK2) is a crucial mediator of cytoskeletal reorganization. However, the potential roles of PLEK2 in gastric cancer are still unknown. PLEK2 expression in gastric cancer was examined by western blotting and real-time PCR. Survival analysis was utilized to test the clinical impacts of the levels of PLEK2 in gastric cancer patients. In vitro and in vivo studies were used to estimate the potential roles played by PLEK2 in modulating gastric cancer proliferation, self-renewal, and tumourigenicity. Bioinformatics approaches were used to monitor the effect of PLEK2 on epithelial-mesenchymal transition (EMT) signalling pathways. PLEK2 expression was significantly upregulated in gastric cancer as compared with nontumour samples. Kaplan-Meier plotter analysis revealed that gastric cancer patients with higher PLEK2 levels had substantially poorer overall survival compared with gastric cancer patients with lower PLEK2 levels. The upregulation or downregulation of PLEK2 in gastric cancer cell lines effectively enhanced or inhibited cell proliferation and proinvasive behaviour, respectively. Additionally, we also found that PLEK2 enhanced EMT through downregulating E-cadherin expression and upregulating Vimentin expression. Our findings demonstrated that PLEK2 plays a potential role in gastric cancer and may be a novel therapeutic target for gastric cancer.


2019 ◽  
Vol 217 (1) ◽  
Author(s):  
Fei Liu ◽  
Jianxin Fu ◽  
Kirk Bergstrom ◽  
Xindi Shan ◽  
J. Michael McDaniel ◽  
...  

Core 1–derived mucin-type O-glycans (O-glycans) are a major component of gastric mucus with an unclear role. To address this, we generated mice lacking gastric epithelial O-glycans (GEC C1galt1−/−). GEC C1galt1−/− mice exhibited spontaneous gastritis that progressed to adenocarcinoma with ∼80% penetrance by 1 yr. GEC C1galt1−/− gastric epithelium exhibited defective expression of a major mucus forming O-glycoprotein Muc5AC relative to WT controls, which was associated with impaired gastric acid homeostasis. Inflammation and tumorigenesis in GEC C1galt1−/− stomach were concurrent with activation of caspases 1 and 11 (Casp1/11)–dependent inflammasome. GEC C1galt1−/− mice genetically lacking Casp1/11 had reduced gastritis and gastric cancer progression. Notably, expression of Tn antigen, a truncated form of O-glycan, and CASP1 activation was associated with tumor progression in gastric cancer patients. These results reveal a critical role of O-glycosylation in gastric homeostasis and the protection of the gastric mucosa from Casp1-mediated gastric inflammation and cancer.


2018 ◽  
Vol Volume 11 ◽  
pp. 25-36 ◽  
Author(s):  
Teming Zhang ◽  
Zheng Han ◽  
Arvine Chandoo ◽  
Xincheng Huang ◽  
Xiangwei Sun ◽  
...  

2018 ◽  
Vol 64 (03/2018) ◽  
Author(s):  
Xiaojuan Ouyang ◽  
Yuan Dang ◽  
Fan Zhang ◽  
Qiaojia Huang

Sign in / Sign up

Export Citation Format

Share Document